Drug Sponsors

O’Connor steps down as CEO of Advaxis

Friday, July 7, 2017

Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc., a late-stage biotechnology company focused on the discovery, development and commercialization of a proprietary Lm-based antigen delivery system, has announced his resignation from the company and its board of directors.

[Read More]

Novomer relocates headquarters to Boston

Monday, July 3, 2017

Novomer, a sustainable chemicals company, has announced the relocation of its headquarters to One Bowdoin Square in Boston on July 17. The new office—designed to meet the expanded demands of the company’s growing bio-based chemicals business—will be in the heart of Boston, less than 20 miles from the current Waltham location.

[Read More]

Lion Biotechnologies changes name to Iovance Biotherapeutics

Monday, July 3, 2017

Iovance Biotherapeutics, a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, changed its corporate name from Lion Biotechnologies to Iovance Biotherapeutics. The company’s new NASDAQ ticker symbol “IOVA” will be effective at the open of the market on June 28, 2017. The former ticker symbol “LBIO” will remain effective through the market close today, June 27, 2017. The new website for Iovance Biotherapeutics is www.iovance.com.

[Read More]

RaNA Therapeutics relaunches as Translate Bio

Monday, July 3, 2017

RaNA Therapeutics has relaunched as Translate Bio (www.translate.bio). The new name stems from the company’s focus on pioneering the translation of RNA science into therapeutics promoting healthy gene expression for people living with debilitating genetic diseases. In addition to its new name, the company also announced the recent leadership appointments of Michael Heartlein, Ph.D., as chief technical officer and Brian Fenton as chief business officer.

[Read More]

Philips to acquire The Spectranetics Corporation

Friday, June 30, 2017

Royal Philips, a global leader in health technology, and The Spectranetics Corporation, a U.S.-based global provider of vascular intervention and lead management solutions, have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for $38.50 per share, to be paid in cash upon completion. This represents a 27% premium to Spectranetics closing price on June 27, 2017. The implied enterprise value is approximately EUR 1.9 billion, inclusive of Spectranetics’ cash and debt. The board of directors of Spectranetics has approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the third quarter of 2017.

[Read More]

Pfizer breaks ground on new R&D facility in Missouri, to hire 80

Thursday, June 29, 2017

Pfizer, a biopharmaceutical company, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.

[Read More]

Flagship Pioneering launches Sigilon Therapeutics

Monday, June 26, 2017

Flagship Pioneering, a fully-integrated life science innovation enterprise, announced the launch of Sigilon Therapeutics. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer technology, a new class of implantable biomaterials that do not trigger fibrosis.

[Read More]

AmerisourceBergen reorganizes

Monday, June 19, 2017

AmerisourceBergen announced a new organizational structure designed to further align the organization to its customer needs in a more seamless and unified way, while supporting corporate strategy and accelerating growth. The company’s customer-facing offerings will now be aligned under two groups:

[Read More]